In an 84-year-old male with a suprapubic catheter on Augmentin 875 mg/125 mg twice daily for presumed urinary tract infection, now presenting with genital itching, groin erythema, leukocytosis, rising creatinine, and a red, swollen, warm leg suggestive of cellulitis, should Augmentin be continued?

Discontinue Augmentin and Broaden Antibiotic Coverage Immediately

This patient requires immediate antibiotic escalation—Augmentin should be discontinued and replaced with IV therapy covering both catheter-associated UTI and presumed cellulitis, given the rising leukocytosis, worsening renal function, and new/uncertain leg findings.

Critical Clinical Assessment

This 84-year-old presents with multiple concerning features that suggest treatment failure or inadequate coverage:

• Rising WBC (12.4 → 15.9) with neutrophilia (ANC 14.7) despite ongoing Augmentin
• Worsening renal function (Cr 1.4 → 1.7)—potentially nephrotoxic from infection or drug effect
• New genital/groin symptoms (itching, erythema)—possible candidal superinfection or drug reaction
• Red, swollen, warm leg—presumed cellulitis of unknown duration/progression
• Suprapubic catheter—defines this as catheter-associated UTI (CA-UTI), a complicated infection 1

The 2024 EAU guidelines are explicit: symptomatic CA-UTI should be treated according to complicated UTI recommendations, which call for IV combination therapy with amoxicillin plus aminoglycoside, second-generation cephalosporin plus aminoglycoside, or IV third-generation cephalosporin 1. Augmentin (oral amoxicillin-clavulanate) is inadequate for this clinical scenario.

Why Augmentin Must Be Stopped

1. Inadequate for Complicated CA-UTI

The EAU guidelines strongly recommend IV therapy for complicated UTI with systemic symptoms 1. While this patient is afebrile, he has:

• Leukocytosis (WBC 15.9)
• Rising creatinine (organ dysfunction)
• Immunosuppression (prednisone)
• Foreign body (suprapubic catheter)

These factors classify him as having complicated CA-UTI requiring parenteral therapy 1.

2. Treatment Failure Indicators

• Rising WBC despite 7+ days of therapy suggests either resistant organism or inadequate drug penetration
• Worsening renal function may indicate ascending infection or drug toxicity
• The UA shows bacteria and leukocyte esterase but no microscopic WBCs—this discordance suggests either dilute urine from catheter irrigation or inadequate specimen collection, but the presence of bacteria with clinical deterioration mandates action

3. Possible Superinfection

Genital itching and groin erythema after prolonged Augmentin therapy raises concern for:

• Candidal superinfection (common with prolonged beta-lactam therapy) 2
• Drug reaction (though less likely given stable vitals)

The FDA label for Augmentin explicitly warns: "The possibility of superinfections with mycotic or bacterial pathogens should be kept in mind during therapy" 2.

4. Cellulitis Requires Different Coverage

The red, swollen, warm leg suggests cellulitis, which typically requires coverage for Streptococcus and Staphylococcus species. While Augmentin covers these organisms, the clinical deterioration (rising WBC, worsening Cr) suggests inadequate response.

Recommended Management Algorithm

Immediate Actions (Within Hours):

1. Obtain blood cultures × 2 before antibiotic change 1
2. Obtain urine culture (if not already done) 1
3. Replace or remove the suprapubic catheter before starting new antimicrobial therapy—this is a strong recommendation from EAU guidelines 1
4. Complete Doppler studies to rule out DVT (alternative diagnosis for leg findings)
5. Examine groin/genital area for candidal infection (KOH prep if discharge present)

Antibiotic Management:

Discontinue Augmentin immediately and initiate:

Option 1 (Preferred for CA-UTI + Cellulitis):

• IV Ceftriaxone 2g daily PLUS Vancomycin (dose-adjusted for renal function, Cr 1.7)
  • Ceftriaxone covers complicated UTI per EAU guidelines 1
  • Vancomycin covers MRSA cellulitis (common in elderly, catheterized patients)
  • Adjust vancomycin dose for CrCl ~40-50 mL/min (estimated from Cr 1.7 in elderly male)

Option 2 (If MRSA risk lower):

• IV Ceftriaxone 2g daily PLUS Gentamicin (dose-adjusted for renal function)
  • Aligns with EAU recommendation for third-generation cephalosporin plus aminoglycoside 1
  • Caution: Gentamicin is nephrotoxic—monitor Cr closely given baseline 1.7

Duration:

• Plan for 7-14 days total therapy (14 days for males when prostatitis cannot be excluded) 1
• If hemodynamically stable and afebrile × 48 hours after IV therapy, consider oral step-down based on culture sensitivities 1

Address Superinfection:

• If candidal infection confirmed: Add fluconazole 200mg loading dose, then 100mg daily
• If drug reaction suspected: Discontinue Augmentin (already done), monitor for resolution

Catheter Management:

The EAU guidelines provide a strong recommendation to replace or remove the indwelling catheter before starting antimicrobial therapy 1. This is critical because:

• Biofilm on catheter harbors bacteria resistant to antibiotics
• Catheter duration is the most important risk factor for CA-UTI 1
• Treatment failure rates are high without catheter replacement

Common Pitfalls to Avoid

1. Continuing oral therapy in complicated CA-UTI: Oral Augmentin is insufficient for this clinical scenario despite being a beta-lactam/beta-lactamase inhibitor combination 1

2. Ignoring catheter replacement: Treating through an old catheter invites treatment failure 1

3. Undertreating based on "afebrile" status: Elderly, immunosuppressed patients (prednisone) may not mount fever despite serious infection. Rising WBC and worsening Cr are your red flags.

4. Assuming UA without WBCs means no infection: In catheterized patients, UA interpretation is complex. The presence of bacteria, leukocyte esterase, and clinical deterioration trumps the absence of microscopic WBCs 3.

5. Ignoring renal function: Cr 1.4 → 1.7 is a 21% increase—this demands dose adjustment of renally cleared antibiotics and raises concern for pyelonephritis or sepsis-related AKI.

Monitoring Parameters

• Daily: Vitals, clinical exam (leg, groin), WBC
• Every 2-3 days: Creatinine, BUN (especially if using aminoglycoside or vancomycin)
• 48-72 hours: Reassess based on culture results and clinical response
• If no improvement in 48-72 hours: Consider imaging (CT abdomen/pelvis) for abscess, obstruction, or alternative diagnosis

The key principle: This patient has complicated CA-UTI with possible concurrent cellulitis and rising markers of infection/organ dysfunction. Oral therapy is inadequate. IV therapy with catheter replacement is mandatory per current guidelines 1.